Dapagliflozin for the treatment of type 2 diabetes

被引：16

作者：

Abdul-Ghani, Muhammad A. ^{[1
]}

DeFronzo, Ralph A. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2013年 / 14卷 / 12期

关键词：

dapagliflozin; kidney; SGLT2; inhibition; sodium-glucose cotransport; type; 2; diabetes; INADEQUATE GLYCEMIC CONTROL; RENAL GLUCOSE REABSORPTION; SELECTIVE SGLT2 INHIBITOR; DOUBLE-BLIND; BODY-WEIGHT; MELLITUS; METFORMIN; INSULIN; PHARMACOKINETICS; PIOGLITAZONE;

D O I：

10.1517/14656566.2013.812632

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. Areas covered: The aim of the present article is to review the efficacy and safety of dapagliflozin, a novel antihyperglycemic drug that lowers the plasma glucose concentration by the inhibition of renal sodium-glucose cotransport, in lowering the plasma glucose concentration and the HbA1c in T2DM patents. This review summarizes the published data about the mechanism of action and clinical efficacy of dapagliflozin in lowering the HbA1c in patients with T2DM. It also discusses additional non-glycemic benefits of dapagliflozin and the safety profile of the drug. Expert opinion: Dapagliflozin is effective in lowering the plasma glucose concentration in patients with T2DM with a good safety profile. Because of its unique mechanism of action, dapagliflozin can be utilized in combination with all other antihyperglycemic agents and at all stages of the disease.

引用

页码：1695 / 1703

页数：9

共 50 条

[21] Dapagliflozin combination therapy in type 2 diabetes mellitus [J].

Yacoub, Tamer .

POSTGRADUATE MEDICINE, 2016, 128 (01) :124-136

[22] SGLT2 inhibition with dapagliflozin A novel approach for the management of type 2 diabetes [J].

Kilov, Gary ;

Leow, Stephen ;

Thomas, Merlin .

AUSTRALIAN FAMILY PHYSICIAN, 2013, 42 (10) :706-710

[23] Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study [J].

Kaku, Kohei ;

Maegawa, Hiroshi ;

Tanizawa, Yukio ;

Kiyosue, Arihiro ;

Ide, Yumiko ;

Tokudome, Takuto ;

Hoshino, Yuji ;

Yang, Jisin ;

Langkilde, Anna Maria .

DIABETES THERAPY, 2014, 5 (02) :415-433

[24] Dapagliflozin for the Treatment of Type 2 Diabetes [J].

Brooks, Arnie McCord ;

Thacker, Stacey M. .

ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) :1286-1293

[25] Dapagliflozin for the treatment of Type 2 diabetes [J].

Woo, Vincent ;

Ho, Janice .

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (05) :435-443

[26] Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes [J].

Lin, Yi ;

Shi, Jianxia ;

Yu, Xuemei ;

Sun, Jiao ;

Lixia, Suo ;

Dou, Jiaqing ;

Zhang, Min ;

Li, Xiaohua ;

Tian, Zhufang ;

Deng, Hongyan ;

Feng, Bo ;

Su, Qing ;

Peng, Yongde .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 :1795-1808

[27] Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C [J].

Skolnik, Neil ;

Bonnes, Harmony ;

Yeh, Helen ;

Katz, Arie .

POSTGRADUATE MEDICINE, 2016, 128 (04) :356-363

[28] Dapagliflozin A Review of its Use in Type 2 Diabetes Mellitus [J].

Plosker, Greg L. .

DRUGS, 2012, 72 (17) :2289-2312

[29] Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea [J].

Park, Sang Hyun ;

Choi, Young Ju ;

Rhee, Eun-Jung ;

Huh, Kab Bum .

ENDOCRINOLOGY AND METABOLISM, 2019, 34 (01) :70-79

[30] Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes [J].

Heerspink, H. J. Lambers ;

de Zeeuw, D. ;

Wie, L. ;

Leslie, B. ;

List, J. .

DIABETES OBESITY & METABOLISM, 2013, 15 (09) :853-862

← 1 2 3 4 5 →